

# Gianluca Gaidano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4636564/publications.pdf>

Version: 2024-02-01

706  
papers

37,680  
citations

2543

96  
h-index

5820

161  
g-index

712  
all docs

712  
docs citations

712  
times ranked

27170  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
2	Analysis of the coding genome of diffuse large B-cell lymphoma. <i>Nature Genetics</i> , 2011, 43, 830-837.	9.4	871
3	Inactivating mutations of acetyltransferase genes in B-cell lymphoma. <i>Nature</i> , 2011, 471, 189-195.	13.7	822
4	p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 5413-5417.	3.3	817
5	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	5.1	723
6	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1389-1401.	4.2	565
7	Genetics of Follicular Lymphoma Transformation. <i>Cell Reports</i> , 2014, 6, 130-140.	2.9	471
8	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	0.6	420
9	Mutations of <i>NOTCH1</i> are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 521-529.	0.6	394
10	Convergent Mutations and Kinase Fusions Lead to Oncogenic <i>STAT3</i> Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	7.7	378
11	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012, 209, 1537-1551.	4.2	363
12	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010, 116, 4745-4753.	0.6	361
13	Mutations of the <i>SF3B1</i> splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , 2011, 118, 6904-6908.	0.6	342
14	p53 mutations are associated with histologic transformation of follicular lymphoma. <i>Blood</i> , 1993, 82, 2289-2295.	0.6	330
15	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 978-988.	5.1	320
16	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401.	0.6	316
17	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	0.8	313
18	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 2139-2147.	0.6	302

#	ARTICLE	IF	CITATIONS
19	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 972-979.	0.8	296
20	The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness. <i>Clinical Cancer Research</i> , 2009, 15, 995-1004.	3.2	284
21	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. <i>Blood</i> , 2014, 124, 2930-2936.	0.6	268
22	Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 26-32.	3.0	261
23	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 2854-2862.	0.6	257
24	Recurrent mutations refine prognosis in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 329-336.	3.3	253
25	Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. <i>Blood</i> , 2003, 101, 4115-4121.	0.6	251
26	The NF- $\kappa$ B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. <i>Blood</i> , 2009, 113, 4918-4921.	0.6	232
27	Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. <i>Blood</i> , 2001, 97, 744-751.	0.6	224
28	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
29	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2413-2425.	0.6	223
30	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. <i>Genome Research</i> , 2009, 19, 438-451.	2.4	218
31	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006, 107, 4643-4649.	0.6	217
32	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682.	0.6	208
33	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2008, 142, 202-215.	1.2	206
34	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	0.8	198
35	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
36	The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. <i>Haematologica</i> , 2013, 98, 953-963.	1.7	195

#	ARTICLE	IF	CITATIONS
37	Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. <i>Blood</i> , 1992, 79, 2981-2989.	0.6	194
38	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.	3.2	189
39	Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. <i>British Journal of Haematology</i> , 1996, 94, 533-543.	1.2	187
40	Diffuse large B-cell lymphoma genotyping on the liquid biopsy. <i>Blood</i> , 2017, 129, 1947-1957.	0.6	183
41	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. <i>Blood</i> , 1993, 81, 166-176.	0.6	182
42	Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2001, 97, 2098-2104.	0.6	181
43	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. <i>Haematologica</i> , 2012, 97, 437-441.	1.7	178
44	Alteration of BIRC3 and multiple other NF- $\kappa$ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011, 118, 4930-4934.	0.6	176
45	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
46	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2006, 132, 303-316.	1.2	169
47	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 730-737.	5.1	164
48	CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 897-904.	0.8	162
49	Primary Mediastinal B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2003, 162, 243-253.	1.9	160
50	Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. <i>Journal of Experimental Medicine</i> , 1989, 170, 613-618.	4.2	157
51	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009.	0.4	153
52	Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53/miR-34a/SIRT1 Tumor Suppressor Network. <i>Cancer Research</i> , 2011, 71, 4473-4483.	0.4	153
53	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 111-123.	0.6	151
54	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151

#	ARTICLE	IF	CITATIONS
55	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	9.4	151
56	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-risk myelodysplastic syndrome and thrombocytopenia. <i>Cancer</i> , 2014, 120, 1838-1846.	2.0	149
57	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 <sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	0.8	149
58	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	0.6	149
59	ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation. <i>Leukemia</i> , 2018, 32, 1070-1080.	3.3	149
60	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	0.6	147
61	Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus Type 8-Positive Solid Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 17-27.	1.2	146
62	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 123.	3.8	143
63	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015, 50, 282-288.	1.3	142
64	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 496-508.	5.1	142
65	Molecular pathogenesis of chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2012, 122, 3432-3438.	3.9	138
66	Biology and treatment of Richter syndrome. <i>Blood</i> , 2018, 131, 2761-2772.	0.6	138
67	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	13.5	138
68	Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. <i>Blood</i> , 2003, 102, 1833-1841.	0.6	137
69	Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. <i>Hematological Oncology</i> , 2005, 23, 61-67.	0.8	136
70	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , 2009, 146, 64-75.	1.2	136
71	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 988-1000.	4.6	136
72	Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 1992, 80, 1781-1787.	0.6	132

#	ARTICLE	IF	CITATIONS
73	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. <i>Blood</i> , 2016, 127, 1007-1016.	0.6	130
74	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1025-1036.	5.1	129
75	Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1376-1385.	0.8	128
76	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124
77	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. <i>Blood</i> , 2011, 118, 6141-6152.	0.6	122
78	Cloning and Gene Mapping of the Chromosome 13q14 Region Deleted in Chronic Lymphocytic Leukemia. <i>Genomics</i> , 1997, 42, 369-377.	1.3	119
79	HHV-8-POSITIVE BODY-CAVITY-BASED LYMPHOMA: A NOVEL LYMPHOMA ENTITY. <i>British Journal of Haematology</i> , 1997, 97, 515-522.	1.2	116
80	Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 4	3.3	116
81	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	0.6	113
82	Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. <i>Blood</i> , 1994, 84, 397-402.	0.6	111
83	Richter syndrome: molecular insights and clinical perspectives. <i>Hematological Oncology</i> , 2009, 27, 1-10.	0.8	109
84	Molecular histogenesis of posttransplantation lymphoproliferative disorders. <i>Blood</i> , 2003, 102, 3775-3785.	0.6	108
85	Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2911-E2919.	3.3	108
86	Azacitidine for the treatment of patients with acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 1014-1022.	2.0	107
87	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
88	Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. <i>British Journal of Haematology</i> , 2002, 117, 366-372.	1.2	106
89	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	1.2	106
90	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , the, 2017, 4, e15-e23.	2.2	106

#	ARTICLE	IF	CITATIONS
91	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	0.6	106
92	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013, 5, 826-837.	2.6	105
93	Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 1060-1070.	3.3	105
94	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , 2009, 23, 1118-1126.	3.3	104
95	Histologic transformation in marginal zone lymphomas. <i>Annals of Oncology</i> , 2015, 26, 2329-2335.	0.6	104
96	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	5.1	100
97	Messengers of cell death: apoptotic signaling in health and disease. <i>Haematologica</i> , 2003, 88, 212-8.	1.7	100
98	Azacitidine for the treatment of lower risk myelodysplastic syndromes. <i>Cancer</i> , 2010, 116, 1485-1494.	2.0	98
99	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 1062-1072.	3.3	97
100	Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1675-1688.	1.0	96
101	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	1.7	96
102	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2020, 10, 20731.	1.6	96
103	Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1266-1273.	1.9	95
104	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. <i>Clinical Cancer Research</i> , 2014, 20, 6398-6405.	3.2	94
105	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	2.0	93
106	Epstein-Barr Virus Infection Is Predictive of CNS Involvement in Systemic AIDS-Related Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 3325-3330.	0.8	92
107	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	1.7	91
108	Different impact of <i>NOTCH1</i> and <i>SF3B1</i> mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2012, 158, 426-429.	1.2	90

#	ARTICLE	IF	CITATIONS
109	Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: Implications for disease pathogenesis and histogenesis. , 1999, 24, 16-23.		89
110	CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2010, 24, 958-969.	3.3	89
111	Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients. <i>Annals of Oncology</i> , 1998, 9, 55-61.	0.6	88
112	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
113	The KrÄppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	3.3	84
114	Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. <i>Blood</i> , 1994, 84, 883-888.	0.6	82
115	Distribution of Kaposi's sarcoma herpesvirus sequences among lymphoid malignancies in Italy and Spain. <i>British Journal of Haematology</i> , 1995, 91, 918-920.	1.2	81
116	<i>MGA</i> , a suppressor of <i>MYC</i> , is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1087-1090.	0.6	81
117	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. <i>Lancet Haematology</i> , 2018, 5, e117-e126.	2.2	81
118	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2417-2426.	1.7	81
119	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , 2016, 6, e493-e493.	2.8	80
120	HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients.. <i>Radiology</i> , 1997, 205, 459-463.	3.6	79
121	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017, 35, 1591-1597.	0.8	79
122	AIDS-Related Burkitt's Lymphoma: Morphologic and Immunophenotypic Study of Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 1995, 103, 561-567.	0.4	78
123	Distribution of human herpesvirus-8 sequences throughout the spectrum of AIDS-related neoplasia. <i>Aids</i> , 1996, 10, 941-949.	1.0	78
124	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2012, 26, 1301-1312.	3.3	78
125	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. <i>Blood</i> , 2014, 123, 2378-2388.	0.6	78
126	Primary effusion lymphoma: A liquid phase lymphoma of fluid-filled body cavities. <i>Advances in Cancer Research</i> , 2001, 80, 115-146.	1.9	77



#	ARTICLE	IF	CITATIONS
127	Molecular histogenesis of plasmablastic lymphoma of the oral cavity. <i>British Journal of Haematology</i> , 2002, 119, 622-628.	1.2	77
128	The miR-17 <sup>1/492</sup> family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. <i>Leukemia</i> , 2012, 26, 1584-1593.	3.3	77
129	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	5.1	76
130	Clinicopathological Consultation Aids-Related Plasmablastic Lymphomas of the Oral Cavity and Jaws: A Diagnostic Dilemma. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 1999, 108, 95-99.	0.6	75
131	Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. <i>Blood</i> , 2006, 108, 1013-1020.	0.6	75
132	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016, 30, 2032-2038.	3.3	75
133	Establishment and characterization of EBV <sup>+</sup> and EBV <sup>-</sup> primary effusion lymphoma cell lines harbouring human herpesvirus type-8. <i>British Journal of Haematology</i> , 1998, 102, 1081-1089.	1.2	74
134	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003, 102, 1035-1041.	0.6	74
135	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189.	3.3	74
136	Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. <i>Haematologica</i> , 2004, 89, 154-64.	1.7	74
137	Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-i IgM cold agglutinins using somatically mutated VH4-21 segments. <i>Blood</i> , 1994, 83, 2952-2961.	0.6	73
138	Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. <i>British Journal of Haematology</i> , 2004, 126, 657-664.	1.2	73
139	CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?. <i>Blood</i> , 2008, 111, 5646-5653.	0.6	73
140	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. <i>Haematologica</i> , 2015, 100, 246-252.	1.7	73
141	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
142	Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines. <i>Leukemia</i> , 1999, 13, 634-640.	3.3	72
143	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 1575-1579.	1.7	72
144	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	0.6	72

#	ARTICLE	IF	CITATIONS
145	Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. <i>Leukemia</i> , 1999, 13, 1093-1099.	3.3	70
146	Genome wide DNAâ€profiling of HIVâ€related Bâ€cell lymphomas. <i>British Journal of Haematology</i> , 2010, 148, 245-255.	1.2	70
147	The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 329-337.	0.9	70
148	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2021, 384, 1810-1823.	13.9	70
149	The mutator pathway is a feature of immunodeficiency-related lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5002-5007.	3.3	68
150	Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice. <i>Cancer Research</i> , 2017, 77, 1250-1260.	0.4	68
151	MUM1: a step ahead toward the understanding of lymphoma histogenesis. <i>Leukemia</i> , 2000, 14, 563-566.	3.3	67
152	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	1.5	67
153	Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. <i>Haematologica</i> , 2006, 91, 1405-9.	1.7	66
154	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009, 94, 1250-1258.	1.7	65
155	Clinical implications of the molecular genetics of chronic lymphocytic leukemia. <i>Haematologica</i> , 2013, 98, 675-685.	1.7	65
156	Richter syndrome: pathogenesis and management. <i>Seminars in Oncology</i> , 2016, 43, 311-319.	0.8	65
157	'Role of bone marrow stromal cells in the growth of human multiple myeloma. <i>Blood</i> , 1991, 77, 2688-2693.	0.6	65
158	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
159	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
160	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	1.3	63
161	Failure of B Cells of Chronic Lymphocytic Leukemia in Presenting Soluble and Alloantigens. <i>Clinical Immunology and Immunopathology</i> , 1995, 75, 26-32.	2.1	62
162	Primary cutaneous large B-cell lymphoma of the leg: Histogenetic analysis of a controversial clinicopathologic entity. <i>Human Pathology</i> , 2002, 33, 937-943.	1.1	62

#	ARTICLE	IF	CITATIONS
163	Comprehensive characterization of IGHV3-21â€‘expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	0.6	62
164	Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. <i>Leukemia</i> , 2017, 31, 115-122.	3.3	61
165	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.2	61
166	Molecular Pathogenesis of Aids-Related Lymphomas. <i>Advances in Cancer Research</i> , 1995, 67, 113-153.	1.9	60
167	Molecular profile of Epsteinâ€‘Barr virus infection in HHV-8-positive primary effusion lymphoma. <i>Leukemia</i> , 2000, 14, 271-277.	3.3	60
168	Clinical Monoclonal B Lymphocytosis versus Rai O Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. <i>Clinical Cancer Research</i> , 2013, 19, 5890-5900.	3.2	60
169	Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?. <i>Blood</i> , 2017, 130, 859-866.	0.6	60
170	Establishment of HHV-8-positive and HHV-8-negative lymphoma cell lines from primary lymphomatous effusions. , 1997, 73, 562-569.		59
171	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	1.2	59
172	Genomeâ€‘wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. <i>British Journal of Haematology</i> , 2008, 143, 532-536.	1.2	58
173	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841.	1.7	58
174	Pathobiology of Primary Mediastinal B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S21-S26.	0.6	57
175	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , 2015, 29, 1360-1365.	3.3	57
176	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059.	0.4	57
177	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <i>Haematologica</i> , 2016, 101, 959-967.	1.7	57
178	Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , 2006, 134, 27-36.	1.2	56
179	Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. <i>British Journal of Haematology</i> , 2000, 111, 247-257.	1.2	56
180	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794.	0.6	55

#	ARTICLE	IF	CITATIONS
181	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2637-2642.	0.6	55
182	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
183	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , 2019, 104, e558-e561.	1.7	55
184	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. <i>Blood</i> , 2021, 137, 646-660.	0.6	55
185	Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2008, 141, 504-511.	1.2	54
186	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 658-661.	0.6	54
187	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013, 98, 1732-1738.	1.7	54
188	Identification of genetic lesions associated with diffuse large-cell lymphoma. <i>Annals of Oncology</i> , 1994, 5, S55-S60.	0.6	53
189	Single nucleotide polymorphism arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 149, 569-577.	1.2	53
190	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	0.6	53
191	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 77-85.	1.7	53
192	Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. <i>American Journal of Hematology</i> , 2016, 91, 995-1001.	2.0	53
193	Simian virus 40 infection in lymphoproliferative disorders. <i>Lancet, The</i> , 2003, 361, 88-89.	6.3	52
194	Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML19). <i>British Journal of Haematology</i> , 2010, 149, 376-382.	1.2	52
195	High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , 2014, 165, 629-639.	1.2	52
196	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
197	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. <i>Blood</i> , 2016, 128, 2093-2095.	0.6	52
198	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. <i>Leukemia</i> , 2017, 31, 2407-2415.	3.3	52

#	ARTICLE	IF	CITATIONS
199	Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. <i>Leukemia</i> , 2017, 31, 1882-1893.	3.3	52
200	Angiotensin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592.	0.6	51
201	Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. <i>Journal of Clinical Pathology</i> , 2002, 55, 684-688.	1.0	50
202	Genetic aberrations of signaling pathways in lymphomagenesis: Revelations from next generation sequencing studies. <i>Seminars in Cancer Biology</i> , 2013, 23, 422-430.	4.3	50
203	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. <i>Leukemia Research</i> , 2015, 39, 296-306.	0.4	50
204	Carfilzomib+dexamethasone vs bortezomib+dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. <i>Leukemia</i> , 2017, 31, 1368-1374.	3.3	50
205	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
206	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , 2022, 23, 865-875.	5.1	50
207	KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. <i>Journal of Clinical Pathology</i> , 2005, 58, 1039-1045.	1.0	49
208	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44.	6.9	49
209	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. <i>Blood</i> , 2015, 125, 3580-3587.	0.6	49
210	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
211	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.	0.6	48
212	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. <i>Blood Advances</i> , 2016, 1, 47-61.	2.5	48
213	Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. <i>American Journal of Hematology</i> , 2018, 93, E243-E246.	2.0	48
214	Annotation AIDS-RELATED LYMPHOMAS: FROM PATHOGENESIS TO PATHOLOGY. <i>British Journal of Haematology</i> , 1995, 90, 235-243.	1.2	47
215	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. <i>Journal of Pathology</i> , 2001, 193, 200-209.	2.1	47
216	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47

#	ARTICLE	IF	CITATIONS
217	Gains of <i>MYC</i> locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , 2011, 155, 274-277.	1.2	47
218	A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. <i>Leukemia</i> , 2011, 25, 1268-1277.	3.3	47
219	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. <i>American Journal of Hematology</i> , 2011, 86, 1007-1012.	2.0	47
220	<i>NOTCH1</i> , <i>SF3B1</i> , <i>BIRC3</i> and <i>TP53</i> mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 2785-2792.	0.6	47
221	Liquid biopsy in lymphoma. <i>Haematologica</i> , 2019, 104, 648-652.	1.7	47
222	BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas. <i>Blood</i> , 1997, 90, 2445-2450.	0.6	46
223	Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. <i>British Journal of Haematology</i> , 2003, 123, 475-478.	1.2	46
224	Genomic profiling of Richter's syndrome: recurrent lesions and differences with <i>de novo</i> diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2010, 28, 62-67.	0.8	46
225	Subcutaneous "lipoma-like" B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , 2010, 21, 1189-1195.	0.6	46
226	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 465-473.	1.2	46
227	<i>EGR2</i> mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 1547-1554.	3.3	46
228	Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. <i>Cancer Research</i> , 2002, 62, 4089-94.	0.4	46
229	Genetic Basis of Acquired Immunodeficiency Syndrome-Related Lymphomagenesis. <i>Journal of the National Cancer Institute Monographs</i> , 1998, 1998, 95-100.	0.9	45
230	Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. <i>Leukemia</i> , 2000, 14, 811-815.	3.3	45
231	Deregulation of <i>ETS1</i> and <i>FLI1</i> contributes to the pathogenesis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 122, 2233-2241.	0.6	45
232	AIDS-Related Extranodal Non-Hodgkin's Lymphomas With Plasma Cell Differentiation. <i>Blood</i> , 1997, 90, 1337-1337.	0.6	44
233	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	3.2	44
234	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016, 101, 941-950.	1.7	44

#	ARTICLE	IF	CITATIONS
235	SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. <i>Journal of Clinical Investigation</i> , 2015, 126, 181-194.	3.9	44
236	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. <i>Haematologica</i> , 2014, 99, 888-896.	1.7	43
237	Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A. <i>Haematologica</i> , 2015, 100, 881-892.	1.7	43
238	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. <i>Haematologica</i> , 2016, 101, 1002-1009.	1.7	43
239	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, .	2.8	43
240	Biologic and molecular characterization of non-Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 1993, 5, 776-784.	1.1	42
241	Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. <i>Blood</i> , 2010, 116, 5957-5960.	0.6	42
242	Genomic profiles of MALT lymphomas: variability across anatomical sites. <i>Haematologica</i> , 2011, 96, 1064-1066.	1.7	42
243	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
244	Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 360-369.	1.7	42
245	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009, 7, 76.	1.8	41
246	Beta $2$ -microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. <i>Cancer</i> , 2010, 116, 2188-2200.	2.0	41
247	E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. <i>Leukemia</i> , 2011, 25, 479-488.	3.3	41
248	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016, 30, 2011-2018.	3.3	41
249	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , 2010, 95, 1144-1149.	1.7	40
250	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599.	1.2	40
251	Mutant p53 blocks SESN1/AMPK/PGC-1 $\beta$ /UCP2 axis increasing mitochondrial O $_2$ production in cancer cells. <i>British Journal of Cancer</i> , 2018, 119, 994-1008.	2.9	40
252	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	0.6	40

#	ARTICLE	IF	CITATIONS
253	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the international extranodal lymphoma study group. British Journal of Haematology, 2014, 166, 69-76.	1.2	39
254	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia, 2018, 32, 1803-1807.	3.3	39
255	HIF-1 $\alpha$ is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	1.7	39
256	Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. Journal of Pathology, 2009, 218, 478-486.	2.1	38
257	Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. Haematologica, 2012, 97, 153-154.	1.7	38
258	Risk factors of central nervous system relapse in mantle cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1908-1914.	0.6	38
259	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. Annals of Oncology, 2014, 25, 447-454.	0.6	38
260	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
261	Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia. Annals of Hematology, 1994, 68, 3-7.	0.8	37
262	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Annals of Neurology, 1999, 45, 259-261.	2.8	37
263	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematology, 2016, 3, e128-e138.	2.2	37
264	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	1.3	37
265	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 2605-2616.	0.8	37
266	Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. Leukemia, 2002, 16, 268-275.	3.3	36
267	Transient monoclonal expansion of CD8+/CD57+ T-cell large granular lymphocytes after primary cytomegalovirus infection. American Journal of Hematology, 2007, 82, 1103-1105.	2.0	36
268	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. Annals of Hematology, 2012, 91, 1013-1022.	0.8	36
269	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18-year follow-up of 488 patients (IELSG 23 study). Annals of Hematology, 2014, 93, 221-231.	0.8	36
270	Human Herpesvirus Type-8 (HHV-8) in Haematopoietic Neoplasia. Leukemia and Lymphoma, 1997, 24, 257-266.	0.6	35



#	ARTICLE	IF	CITATIONS
271	Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. <i>British Journal of Haematology</i> , 2002, 119, 923-929.	1.2	35
272	The Human Marginal Zone B Cell. <i>Annals of the New York Academy of Sciences</i> , 2003, 987, 117-124.	1.8	35
273	Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2004, 18, 1941-1947.	3.3	35
274	Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: A single center experience. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 31-42.	2.0	35
275	Biologic aspects of human immunodeficiency virus-related lymphoma. <i>Current Opinion in Oncology</i> , 1992, 4, 900-906.	1.1	34
276	Is Plasmablastic Lymphoma of the Oral Cavity an HHV-8-associated Disease?. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1538-1540.	2.1	34
277	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	0.8	34
278	A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. <i>European Journal of Haematology</i> , 2016, 96, 352-359.	1.1	34
279	The clinical implications of gene mutations in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2016, 114, 849-854.	2.9	34
280	Clinical impact of small subclones harboring <i>NOTCH1</i> , <i>SF3B1</i> or <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e135-e138.	1.7	34
281	Point mutations of the BCL-6 gene in Burkitt's lymphoma. <i>British Journal of Haematology</i> , 1997, 99, 168-170.	1.2	33
282	Cloning and Mapping of Human Chromosome 6q26-q27 Deleted in B-Cell Non-Hodgkin Lymphoma and Multiple Tumor Types. <i>Genomics</i> , 1998, 50, 170-186.	1.3	33
283	The tyrosine kinase receptor Met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. <i>Leukemia</i> , 2000, 14, 285-291.	3.3	33
284	Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38 <sup>+</sup> CD49d <sup>+</sup> chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2010, 150, 111-112.	1.2	33
285	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	1.1	33
286	Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1001-1009.	1.1	33
287	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	0.6	33
288	Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. <i>FASEB Journal</i> , 1993, 7, 951-956.	0.2	32

#	ARTICLE	IF	CITATIONS
289	Molecular heterogeneity of B-lineage diffuse large cell lymphoma. , 1996, 16, 21-30.		32
290	High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. British Journal of Haematology, 2008, 141, 622-630.	1.2	32
291	Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica, 2008, 93, 697-705.	1.7	32
292	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. Seminars in Hematology, 2014, 51, 168-176.	1.8	32
293	Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood, 2015, 126, 1043-1044.	0.6	32
294	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer Journal, 2018, 8, 108.	2.8	32
295	Analysis of Human Herpesvirus Type 8 Infection in AIDS-Related and AIDS-Unrelated Primary Central Nervous System Lymphoma. Journal of Infectious Diseases, 1997, 175, 1193-1197.	1.9	31
296	Primary Effusion Lymphoma Cell Lines Harboring Human Herpesvirus Type-8. Leukemia and Lymphoma, 2000, 36, 447-456.	0.6	31
297	Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leukemia and Lymphoma, 2013, 54, 2485-2489.	0.6	31
298	Lenalidomide~prednisone induction followed by lenalidomide~melphalan~prednisone consolidation and lenalidomide~prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia, 2013, 27, 695-701.	3.3	31
299	Life expectancy of young adults with follicular lymphoma. Annals of Oncology, 2015, 26, 2317-2322.	0.6	31
300	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF- $\kappa$ B pathways. Leukemia, 2018, 32, 654-662.	3.3	31
301	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer, 2018, 124, 1251-1259.	2.0	31
302	Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica, 2004, 89, 759-61.	1.7	31
303	A new TaqI polymorphism in the p53 gene. Nucleic Acids Research, 1992, 20, 928-928.	6.5	30
304	Cytogenetic and molecular analysis of 6q deletions in burkitt's lymphoma cell lines. Genes Chromosomes and Cancer, 1994, 9, 13-18.	1.5	30
305	Analysis of microsatellite instability in chronic lymphoproliferative disorders. Annals of Hematology, 1996, 72, 67-71.	0.8	30
306	Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma. Annals of Oncology, 1997, 8, 987-994.	0.6	30

#	ARTICLE	IF	CITATIONS
307	Detection of BCL-6 rearrangements and p53 mutations in malt-lymphomas. , 1997, 56, 206-213.		30
308	Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 604-611.	0.6	30
309	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 117, 2405-2413.	0.6	30
310	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	1.2	30
311	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99.	0.8	30
312	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	1.2	30
313	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
314	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30
315	Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 106-111.	1.5	29
316	Proliferation in HHV-8-Positive Primary Effusion Lymphomas Is Associated with Expression of HHV-8 Cyclin but Independent of p27kip1. <i>American Journal of Pathology</i> , 2000, 156, 1209-1215.	1.9	29
317	Genetic pathways and histogenetic models of AIDS-related lymphomas. <i>European Journal of Cancer</i> , 2001, 37, 1270-1275.	1.3	29
318	Molecular Heterogeneity of Diffuse Large B-cell Lymphoma: Implications for Disease Management and Prognosis. <i>Hematology</i> , 2002, 7, 239-252.	0.7	29
319	Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. <i>Leukemia</i> , 2005, 19, 2363-2366.	3.3	29
320	Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. <i>Journal of Pathology</i> , 2005, 206, 87-91.	2.1	29
321	JAK2V617F mutation in leukaemic transformation of Philadelphia-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2006, 135, 267-268.	1.2	29
322	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41.	0.8	29
323	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. <i>Haematologica</i> , 2014, 99, 1611-1617.	1.7	29
324	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020, 105, 2592-2597.	1.7	29

#	ARTICLE	IF	CITATIONS
325	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2011, 152, 284-294.	1.2	28
326	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , 2012, 130, 3006-3010.	2.3	28
327	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018, 53, 461-473.	1.3	28
328	Precision Medicine Management of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 642.	1.7	28
329	Diffuse large cell lymphomas exhibit frequent deletions in 9p21 and 9q31-34 regions. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 32-36.	1.5	27
330	Differential regulation of Notch signal transduction in leukaemia and lymphoma cells in culture. <i>Journal of Cellular Biochemistry</i> , 2003, 88, 569-577.	1.2	27
331	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 wild-type CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	1.2	27
332	ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter. <i>Haematologica</i> , 2012, 97, 5-8.	1.7	27
333	Analysis of <i>SF3B1</i> mutations in monoclonal B-cell lymphocytosis. <i>Hematological Oncology</i> , 2013, 31, 54-55.	0.8	27
334	Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. <i>British Journal of Haematology</i> , 2014, 167, 718-720.	1.2	27
335	Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. <i>Blood</i> , 2014, 124, 3831-3833.	0.6	27
336	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 5292-5301.	3.2	27
337	Atypical Chronic Myeloid Leukemia: Where Are We Now?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6862.	1.8	27
338	Subregional Localization of 20 Single-Copy Loci to Chromosome 6 by Fluorescence in Situ Hybridization. <i>Genomics</i> , 1993, 16, 426-430.	1.3	26
339	Expression of prolactin and prolactin receptors by non-Hodgkin's lymphoma cells. <i>International Journal of Cancer</i> , 2000, 85, 124-130.	2.3	26
340	HHV-8/KSHV is Not Associated with AIDS-Related Primary Central Nervous System Lymphoma. <i>Brain Pathology</i> , 1999, 9, 199-208.	2.1	26
341	Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. <i>Haematologica</i> , 2008, 93, 1178-1185.	1.7	26
342	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26

#	ARTICLE	IF	CITATIONS
343	Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009375.	2.1	26
344	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 393-393.	0.6	26
345	Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. <i>Journal of Clinical Virology</i> , 2000, 16, 215-224.	1.6	25
346	Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2004, 127, 322-325.	1.2	25
347	Richter Syndrome. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 173-191.	0.8	25
348	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	0.8	25
349	Italian external and multicentric validation of the <i>MD Anderson C</i> cancer <i>C</i> enter nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. <i>British Journal of Haematology</i> , 2014, 167, 224-232.	1.2	25
350	Molecular pathology of AIDS-related lymphomas. <i>Annals of Hematology</i> , 1994, 69, 281-290.	0.8	24
351	AIDS-Related Non-Hodgkin's Lymphomas: Molecular Genetics, Viral Infection and Cytokine Deregulation. <i>Acta Haematologica</i> , 1996, 95, 193-198.	0.7	24
352	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018, 245, 61-73.	2.1	24
353	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	2.0	24
354	Integrated epigenomic and transcriptomic analysis reveals <i>TP63</i> as a novel player in clinically aggressive chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 144, 2695-2706.	2.3	24
355	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. <i>Leukemia</i> , 2020, 34, 462-477.	3.3	24
356	Investigational drugs for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 25-38.	1.9	24
357	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. <i>Disease Markers</i> , 2021, 2021, 1-7.	0.6	24
358	High frequency of EBV association with non-random abnormalities of the chromosome region 1q21-25 in aids-related Burkitt's lymphoma-derived cell lines. <i>International Journal of Cancer</i> , 1995, 61, 370-374.	2.3	23
359	Patterns of cytokine expression in AIDS-related non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1998, 103, 143-149.	1.2	23
360	Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas. <i>European Journal of Immunology</i> , 1999, 29, 2863-2874.	1.6	23

#	ARTICLE	IF	CITATIONS
361	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	0.6	23
362	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1.	0.2	23
363	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3150-3158.	0.6	23
364	Microsatellite instability in KSHV/HHV-8 positive body-cavity-based lymphoma. <i>Human Pathology</i> , 1997, 28, 748-750.	1.1	22
365	A role for growth hormone and prolactin in leukaemia and lymphoma?. <i>Cellular and Molecular Life Sciences</i> , 1998, 54, 1095-1101.	2.4	22
366	Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: Pathogenetic and histogenetic implications. <i>Human Pathology</i> , 2000, 31, 871-873.	1.1	22
367	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504.	1.7	22
368	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	0.6	22
369	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.	1.2	22
370	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
371	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	1.7	22
372	Herpesvirus-like DNA sequences selectively cluster with body cavity-based lymphomas throughout the spectrum of AIDS-related lymphomatous effusions. <i>European Journal of Cancer</i> , 1996, 32, 555-556.	1.3	21
373	Centromeric instability of chromosome 1 resulting in multibranching chromosomes, telomeric fusions, and "jumping translocations" of 1q in a human immunodeficiency virus-related non-Hodgkin's lymphoma. <i>Journal of Cellular Biochemistry</i> , 1996, 78, 1142-1143.		21
374	Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. <i>Leukemia</i> , 2001, 15, 186-187.	3.3	21
375	Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. <i>British Journal of Haematology</i> , 2007, 138, 249-252.	1.2	21
376	Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. <i>British Journal of Haematology</i> , 2008, 141, 734-736.	1.2	21
377	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2012, 10, 18.	1.8	21
378	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856.	1.7	21

#	ARTICLE	IF	CITATIONS
379	Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. <i>Oncotarget</i> , 2015, 6, 18653-18663.	0.8	21
380	Subregional mapping of 8 single copy loci to chromosome 6 by fluorescence in situ hybridization. <i>Cytogenetic and Genome Research</i> , 1994, 66, 272-273.	0.6	20
381	Similarities and Differences Between the Light and Heavy Chain Ig Variable Region Gene Repertoires in Chronic Lymphocytic Leukemia. <i>Molecular Medicine</i> , 2006, 12, 300-308.	1.9	20
382	Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2007, 48, 158-167.	0.6	20
383	<i>JAK2</i> V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia. <i>British Journal of Haematology</i> , 2007, 138, 813-814.	1.2	20
384	Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. <i>Journal of Infection</i> , 2007, 54, 298-306.	1.7	20
385	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	1.2	20
386	Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. <i>Haematologica</i> , 2011, 96, 1496-1503.	1.7	20
387	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012, 30, 46-49.	0.8	20
388	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B cell receptor structure, function, and patients' prognosis. <i>American Journal of Hematology</i> , 2014, 89, 74-82.	2.0	20
389	Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. <i>British Journal of Haematology</i> , 2016, 172, 371-383.	1.2	20
390	The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , 2019, 104, 1004-1015.	1.7	20
391	Targeting p53 in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1239-1250.	1.5	20
392	Burkitt's Lymphoma: Historical Background and Recent Insights into Classification and Pathogenesis. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2000, 109, 693-702.	0.6	19
393	The Role of Cytokines in the Pathogenesis and Management of Aids-Related Lymphomas. <i>Leukemia and Lymphoma</i> , 2000, 38, 481-488.	0.6	19
394	Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. <i>Hematological Oncology</i> , 2006, 24, 212-219.	0.8	19
395	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23.	1.8	19
396	Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. <i>British Journal of Haematology</i> , 2011, 154, 229-233.	1.2	19

#	ARTICLE	IF	CITATIONS
397	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012, 23, 729-735.	0.6	19
398	Promoter methylation patterns in Richter syndrome affect stem cell maintenance and cell cycle regulation and differ from <i>de novo</i> diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 194-204.	1.2	19
399	Lymphocytosis and ibrutinib treatment of CLL. <i>Blood</i> , 2014, 123, 1772-1774.	0.6	19
400	PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization. <i>Hematological Oncology</i> , 2015, 33, 125-132.	0.8	19
401	Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?. <i>Haematologica</i> , 2016, 101, 263-265.	1.7	19
402	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , 2018, 29, 966-972.	0.6	19
403	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B cell lymphoma patients treated in the FILDLCL04 trial. <i>British Journal of Haematology</i> , 2022, 196, 1184-1193.	1.2	19
404	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
405	Molecular Defects Associated with the Acute Phase CML. <i>Leukemia and Lymphoma</i> , 1993, 11, 25-28.	0.6	18
406	Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an Italian expert panel. <i>Advances in Therapy</i> , 2011, 28, 684-697.	1.3	18
407	Genome-wide high resolution DNA profiling of hairy cell leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 566-569.	1.2	18
408	Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	1.7	18
409	Comparison between the CLL-IPI and the Barcelona prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018, 93, E35-E37.	2.0	18
410	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , 2019, 22, 1303-1310.	0.1	18
411	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	1.2	18
412	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020, 189, 853-859.	1.2	18
413	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2015, 6, 19102-19117.	0.8	18
414	Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. <i>International Journal of Biological Markers</i> , 2003, 18, 218-221.	0.7	18



#	ARTICLE	IF	CITATIONS
415	Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). <i>Leukemia Research</i> , 2006, 30, 1197-1199.	0.4	17
416	Clinical and molecular features of mucosa-associated lymphoid tissue (MALT) lymphomas of salivary glands. <i>Head and Neck</i> , 2009, 31, 1181-1187.	0.9	17
417	The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. <i>International Journal of Cancer</i> , 2009, 125, 2360-2366.	2.3	17
418	Predictive markers and driving factors behind Richter syndrome development. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 433-442.	1.1	17
419	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3323-3334.	0.9	17
420	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 859-865.	0.4	17
421	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
422	Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: Correlation with chemotherapy intensity and clinical outcome. <i>Leukemia Research</i> , 1996, 20, 441-443.	0.4	16
423	Characterization of Epstein-Barr Virus Genotype in AIDS-Related Non-Hodgkin's Lymphoma. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 19-26.	0.5	16
424	Genome-wide promoter methylation of hairy cell leukemia. <i>Blood Advances</i> , 2019, 3, 384-396.	2.5	16
425	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
426	New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7542.	1.8	16
427	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. <i>Genes Chromosomes and Cancer</i> , 1997, 19, 250-255.	1.5	15
428	Lymphoid disorders associated with HHV-8/KSHV infection: facts and contentions. <i>Medical Oncology</i> , 1999, 16, 8-12.	1.2	15
429	Acquired immunodeficiency syndrome-related cancer. A study model for the mechanisms contributing to the genesis of cancer. <i>European Journal of Cancer</i> , 2001, 37, 1184-1187.	1.3	15
430	Differences in the Expression of Apoptotic Proteins in Burkitt's Lymphoma Cell Lines: Potential Models for Screening Apoptosis-Inducing Agents. <i>Leukemia and Lymphoma</i> , 2004, 45, 357-362.	0.6	15
431	Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance. <i>Clinical Cancer Research</i> , 2009, 15, 4439-4445.	3.2	15
432	<i>BCL2</i> mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. <i>Hematological Oncology</i> , 2015, 33, 23-30.	0.8	15

#	ARTICLE	IF	CITATIONS
433	Potential of BCL2 as a target for chronic lymphocytic leukemia treatment. Expert Review of Hematology, 2018, 11, 391-402.	1.0	15
434	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American Journal of Hematology, 2018, 93, E216-E219.	2.0	15
435	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. Annals of Hematology, 2018, 97, 1767-1774.	0.8	15
436	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. Blood, 2021, 138, 2290-2293.	0.6	15
437	Post-Transplant Lymphoproliferative Disorders: Role Of Viral Infection, Genetic Lesions And Antigen Stimulation In The Pathogenesis Of The Disease. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009018.	0.5	15
438	p53 Mutation in a Case of Blastic Transformation of Follicular Lymphoma with Double bcl-2 Rearrangement (MBR and VCR). Leukemia and Lymphoma, 1998, 29, 595-605.	0.6	14
439	Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia. Blood, 2008, 111, 466-468.	0.6	14
440	Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Reports, 2011, 2011, bcr1120103549-bcr1120103549.	0.2	14
441	Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. European Journal of Haematology, 2011, 87, 409-418.	1.1	14
442	Molecular genetics of high-risk chronic lymphocytic leukemia. Expert Review of Hematology, 2012, 5, 593-602.	1.0	14
443	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica, 2012, 97, 849-853.	1.7	14
444	Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. Hematological Oncology, 2013, 31, 22-28.	0.8	14
445	Clinical significance of c.7544â€¦7545 del<sc>CT</sc><i><sc>NOTCH</sc>1</i> mutation in chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 160, 415-418.	1.2	14
446	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	6.9	14
447	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 1669-1669.	0.6	14
448	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. Journal of the National Cancer Institute, 2022, 114, 979-987.	3.0	14
449	Genetic heterogeneity of AIDS-related small non-cleaved cell lymphoma. British Journal of Haematology, 1997, 98, 726-732.	1.2	13
450	High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. Cytometry, 1997, 30, 33-38.	1.8	13

#	ARTICLE	IF	CITATIONS
451	BCL-6 in Aids-Related Lymphomas: Pathogenetic and Histogenetic Implications. <i>Leukemia and Lymphoma</i> , 1998, 31, 39-46.	0.6	13
452	B-cell Posttransplant Lymphoproliferative Disorders in Heart and/or Lungs Recipients: Clinical and Molecular-Histogenetic Study of 17 Cases from a Single Institution. <i>Transplantation</i> , 2006, 82, 1013-1023.	0.5	13
453	Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia. <i>Haematologica</i> , 2010, 95, 1992-1995.	1.7	13
454	Analysis of the <i>REL</i> , <i>BCL11A</i> , and <i>MYCN</i> proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2010, 85, 541-544.	2.0	13
455	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , 2013, 24, 1378-1384.	0.6	13
456	Analysis of human $\beta$ -papillomavirus and Merkel cell polyomavirus infection in skin lesions and eyebrow hair bulbs from a cohort of patients with chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 2014, 171, 1525-1528.	1.4	13
457	Unbiased pro-thrombotic features at diagnosis in 977 thrombocytopenic patients with Philadelphia-negative chronic myeloproliferative neoplasms. <i>Leukemia Research</i> , 2016, 46, 18-25.	0.4	13
458	Short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. <i>Blood Cancer Journal</i> , 2016, 6, e425-e425.	2.8	13
459	FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. <i>Leukemia and Lymphoma</i> , 2017, 58, 372-381.	0.6	13
460	Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. <i>Leukemia</i> , 2021, 35, 2325-2331.	3.3	13
461	Safety and Efficacy from a Phase 1b/2 Study of IMG632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 372-372.	0.6	13
462	Molecular Pathways in Low Grade B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1997, 26, 107-113.	0.6	12
463	14q32 Translocations and risk of Richter transformation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 144, 131-133.	1.2	12
464	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503.	1.2	12
465	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. <i>Quality of Life Research</i> , 2020, 29, 815-823.	1.5	12
466	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12
467	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	1.7	12
468	Eltrombopag for the Treatment of Aplastic Anemia in Europe. <i>Blood</i> , 2018, 132, 1304-1304.	0.6	12

#	ARTICLE	IF	CITATIONS
469	Pathological and immunophenotypic features of adult non-Hodgkin's lymphomas by age group. <i>Human Pathology</i> , 1997, 28, 580-587.	1.1	11
470	Expression of Cyclin-Dependent Kinase Inhibitor p27Kip1 in AIDS-Related Diffuse Large-Cell Lymphomas Is Associated with Epstein-Barr Virus-Encoded Latent Membrane Protein 1. <i>American Journal of Pathology</i> , 2002, 161, 163-171.	1.9	11
471	A phase II study of $\hat{\pm}$ -interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. <i>Leukemia</i> , 2003, 17, 554-559.	3.3	11
472	Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. <i>British Journal of Haematology</i> , 2005, 130, 92-95.	1.2	11
473	Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-associated polyclonal body cavity effusions that mimic primary effusion lymphomas. <i>International Journal of Cancer</i> , 2006, 119, 1746-1748.	2.3	11
474	Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera. <i>Leukemia Research</i> , 2007, 31, 97-101.	0.4	11
475	KSHV/HHV8 Doesn't Play a Significant Role in the Development of Plasmablastic Lymphoma of the Oral Cavity. <i>American Journal of Surgical Pathology</i> , 2008, 32, 172-174.	2.1	11
476	THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012076.	0.5	11
477	The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. <i>Blood</i> , 2012, 119, 2106-2109.	0.6	11
478	Absence of <i>NOTCH1</i> gene mutations in MALT lymphomas. <i>British Journal of Haematology</i> , 2012, 157, 382-384.	1.2	11
479	CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2013, 27, 1177-1181.	3.3	11
480	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	1.7	11
481	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	0.6	11
482	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019, 81, 88-94.	0.4	11
483	Methods for Measuring ctDNA in Lymphomas. <i>Methods in Molecular Biology</i> , 2019, 1881, 253-265.	0.4	11
484	Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, , .	1.7	11
485	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2016, 16, 659-668.	0.8	11
486	Na <sup>+</sup> /H <sup>+</sup> antiporter has different properties in human B lymphocytes according to CD5 expression and malignant phenotype. <i>European Journal of Immunology</i> , 1991, 21, 583-588.	1.6	10

#	ARTICLE	IF	CITATIONS
487	High Frequency of CD45RO Expression in AIDS-Related B-Cell Non-Hodgkin's Lymphomas. American Journal of Clinical Pathology, 1995, 104, 680-688.	0.4	10
488	Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. British Journal of Haematology, 1997, 96, 308-313.	1.2	10
489	Most immunoglobulin heavy chain switch mu rearrangements in B-cell chronic lymphocytic leukemia are internal deletions. FEBS Letters, 2002, 518, 119-123.	1.3	10
490	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. American Journal of Hematology, 2010, 85, 619-622.	2.0	10
491	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 71-76.	0.6	10
492	Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunology Letters, 2013, 155, 51-55.	1.1	10
493	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. Leukemia, 2014, 28, 705-708.	3.3	10
494	Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance. Hematological Oncology, 2014, 32, 133-138.	0.8	10
495	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematological Oncology, 2018, 36, 600-603.	0.8	10
496	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. British Journal of Haematology, 2019, 185, 330-334.	1.2	10
497	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	2.0	10
498	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. Blood, 2018, 132, 43-43.	0.6	10
499	Molecular Pathogenesis of B-Cell Chronic Lymphocytic Leukemia: Analysis of 13q14 Chromosomal Deletions. Current Topics in Microbiology and Immunology, 2000, 252, 275-284.	0.7	10
500	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. British Journal of Haematology, 2022, 198, 1016-1022.	1.2	10
501	Potential heterosexual Kaposi's sarcoma-associated herpesvirus transmission in a couple with HIV-induced immunodepression and with Kaposi's sarcoma and multicentric Castleman's disease. Aids, 1996, 10, 1291-1292.	1.0	9
502	Structural abnormality of 1q in an AIDS-related body-cavity-based lymphoma. , 1996, 67, 588-590.		9
503	Distribution of TP53 mutations among acute leukemias with MLL rearrangements. , 1996, 15, 48-53.		9
504	Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. , 2000, 27, 177-182.		9

#	ARTICLE	IF	CITATIONS
505	Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: Resolution with rituximab. <i>Leukemia Research</i> , 2008, 32, 829-834.	0.4	9
506	CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. <i>Future Oncology</i> , 2008, 4, 355-358.	1.1	9
507	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010, 51, 822-838.	0.6	9
508	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. <i>Mechanisms of Ageing and Development</i> , 2012, 133, 479-488.	2.2	9
509	Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. <i>British Journal of Haematology</i> , 2012, 156, 354-357.	1.2	9
510	Globalisation of clinical trials and ethics of benefit sharing. <i>Lancet Haematology</i> , 2014, 1, e54-e56.	2.2	9
511	Biallelic <i>BIRC3</i> inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , 2019, 185, 156-159.	1.2	9
512	Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome. <i>British Journal of Haematology</i> , 2019, 187, 478-487.	1.2	9
513	Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib. <i>British Journal of Haematology</i> , 2019, 184, 392-396.	1.2	9
514	Genome Wide-DNA Profiling of HIV-Related Non-Hodgkin Lymphomas: Implications for Disease Pathogenesis and Histogenesis. <i>Blood</i> , 2007, 110, 561-561.	0.6	9
515	A 2-Mb YAC Contig Linking the Plasminogen-Apoprotein(a) Gene Family to the Insulin-like Growth Factor 2 Receptor (IGF2R) Gene on the Telomeric Region of Chromosome 6 (6q26-q27). <i>Genomics</i> , 1994, 22, 664-666.	1.3	8
516	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2003, 107, 958-961.	2.3	8
517	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , 2008, 22, 224-226.	3.3	8
518	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1786-1787.	0.6	8
519	Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2017, 176, 258-267.	1.2	8
520	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	3.3	8
521	Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with standard-immunotherapy: A large retrospective study from 4 institutions. <i>Hematological Oncology</i> , 2018, 36, 84-92.	0.8	8
522	Predictive value of the CLL-IPI in CLL patients receiving chemoimmunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706.	1.1	8

#	ARTICLE	IF	CITATIONS
523	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
524	<i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8
525	Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients. <i>Blood</i> , 2016, 128, 1214-1214.	0.6	8
526	An Apparent Interlocus Gene Conversion-like Event at a Putative Tumor Suppressor Gene Locus on Human Chromosome 6q27 in a Burkitt's Lymphoma Cell Line. <i>DNA Research</i> , 2000, 7, 261-272.	1.5	7
527	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency. <i>British Journal of Haematology</i> , 2004, 124, 604-609.	1.2	7
528	Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 321-329.	1.5	7
529	Cellular Origin, Antigen Reactivity, and V <sub>H</sub> Segment Structure of IgM mAbs from AIDS Lymphomas. <i>Annals of the New York Academy of Sciences</i> , 1995, 764, 509-518.	1.8	7
530	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	0.6	7
531	An update on: molecular genetics of high-risk chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 109-116.	1.0	7
532	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	2.8	7
533	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
534	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3695-3703.	3.2	7
535	Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 108-112.	1.2	7
536	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585.	0.6	7
537	Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. <i>Blood</i> , 2016, 128, 623-623.	0.6	7
538	Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7521-7521.	0.8	7
539	Involvement of the bcl-6 gene in AIDS-related lymphomas. <i>Annals of Oncology</i> , 1997, 8, S105-S108.	0.6	6
540	Are Gilbert's syndrome and liver involvement genetically linked in infectious mononucleosis?. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, 1110-1111.	1.1	6

#	ARTICLE	IF	CITATIONS
541	Hairy cell leukaemia complicated by anti-MAG paraproteinemic demyelinating neuropathy: resolution of neurological syndrome after cladribine treatment. <i>Leukemia Research</i> , 2007, 31, 873-876.	0.4	6
542	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	1.7	6
543	Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 755-757.	0.6	6
544	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	1.3	6
545	Anti- <i>Er</i> asburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. <i>Hematological Oncology</i> , 2020, 38, 204-206.	0.8	6
546	Inducible T- <i>cell</i> co- <i>stimulator</i> (ICOS) and ICOS ligand are novel players in the multiple- <i>myeloma</i> microenvironment. <i>British Journal of Haematology</i> , 2022, 196, 1369-1380.	1.2	6
547	A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation. <i>Nature Communications</i> , 2022, 13, 2042.	5.8	6
548	Circulating malignant precursors in monoclonal gammopathies. <i>European Journal of Haematology</i> , 1989, 43, 27-29.	1.1	5
549	Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia. <i>American Journal of Hematology</i> , 2009, 84, 697-698.	2.0	5
550	Impact of the host genetic background on prognosis of chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 1106-1107.	0.6	5
551	correspondence: <i>&lt;i&gt;BCL3&lt;/i&gt;</i> translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance. <i>British Journal of Haematology</i> , 2010, 150, 702-704.	1.2	5
552	Hepatitis B virus and lymphomagenesis: Novel insights into an occult relationship. <i>Digestive and Liver Disease</i> , 2012, 44, 235-238.	0.4	5
553	Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. <i>Leukemia</i> , 2019, 33, 1801-1805.	3.3	5
554	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168.	1.7	5
555	Frequency and clinical relevance of coding and noncoding <i>&lt;i&gt;NOTCH1&lt;/i&gt;</i> mutations in early stage Binet A chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2020, 38, 406-408.	0.8	5
556	Comparison of ibrutinib and idelalisib plus rituximab in real- <i>life</i> relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
557	A randomized clinical study on the impact of Comprehensive Geriatric Assessment (CGA) based interventions on the quality of life of elderly, frail, onco-hematologic patients candidate to anticancer therapy: protocol of the ONCO-Aging study. <i>BMC Geriatrics</i> , 2021, 21, 320.	1.1	5
558	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , 2021, 39, 707-711.	0.8	5



#	ARTICLE	IF	CITATIONS
559	Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	0.6	5
560	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 1940-1940.	0.6	5
561	Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab. <i>Blood</i> , 2012, 120, 1637-1637.	0.6	5
562	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 90013-90027.	0.8	5
563	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients. <i>Blood Cancer Journal</i> , 2022, 12, 8.	2.8	5
564	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
565	Molecular Pathogenesis of AIDS-Related Lymphomas1. <i>Antibiotics and Chemotherapy</i> , 1994, 46, 117-124.	0.5	4
566	Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. <i>British Journal of Haematology</i> , 2000, 111, 247-257.	1.2	4
567	Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure. <i>American Journal of Hematology</i> , 2010, 85, 461-462.	2.0	4
568	Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2011, 35, 1419-1422.	0.4	4
569	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the <i>MLL/ENL</i> fusion gene. <i>American Journal of Hematology</i> , 2011, 86, 993-997.	2.0	4
570	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2014, 99, e159-e161.	1.7	4
571	II. Challenges in the management of post-transplant lymphoproliferative disorder. <i>Hematological Oncology</i> , 2015, 33, 96-99.	0.8	4
572	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2687.	2.0	4
573	Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. <i>Leukemia and Lymphoma</i> , 2016, 57, 400-410.	0.6	4
574	Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of <i>SF3B1</i> gene refines prognosis in treatment-naïve chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e144-e147.	1.7	4
575	Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. <i>Leukemia</i> , 2018, 32, 543-546.	3.3	4
576	Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , 2018, 36, 757-764.	0.8	4

#	ARTICLE	IF	CITATIONS
577	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. <i>Cancers</i> , 2020, 12, 1773.	1.7	4
578	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
579	Intravascular lymphoma: from vessels to genes. <i>Blood</i> , 2021, 137, 1438-1439.	0.6	4
580	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	2.0	4
581	Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. <i>Blood</i> , 2018, 132, 46-46.	0.6	4
582	Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 5454-5454.	0.6	4
583	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611.	0.6	4
584	Precision Medicine in Systemic Mastocytosis. <i>Medicina (Lithuania)</i> , 2021, 57, 1135.	0.8	4
585	Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7507-7507.	0.8	4
586	Factor VIII as a potential player in cancer pathophysiology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 648-660.	1.9	4
587	Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study. <i>Blood</i> , 2020, 136, 21-22.	0.6	4
588	SacI RFLP in the insulin-like growth factor 2 receptor gene (IGF2R) on human chromosome 6q. <i>Nucleic Acids Research</i> , 1991, 19, 6974-6974.	6.5	3
589	TaqI RFLP in the interferon gamma receptor 1 gene (IFNGR1) on human chromosome 6q. <i>Nucleic Acids Research</i> , 1992, 20, 1158-1158.	6.5	3
590	Expression of BCL-6 Protein and Cd138/Syndecan-1 as B-Cell Markers in Hodgkin'S Disease. <i>International Journal of Biological Markers</i> , 1999, 14, 144-148.	0.7	3
591	Simian AIDS-Related Lymphoma Growth in Severe Combined Immunodeficiency Mice Is Independent of Karyotypic Abnormalities orBcl-6Mutations. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 383-390.	0.5	3
592	Simultaneous diagnosis of CD3+ T-cell large granular lymphocyte leukaemia and true thymic hyperplasia. <i>Leukemia Research</i> , 2007, 31, 1019-1021.	0.4	3
593	Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , 2010, 34, e243-e245.	0.4	3
594	In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. <i>Hematological Oncology</i> , 2011, 29, 164-166.	0.8	3

#	ARTICLE	IF	CITATIONS
595	<i>ARHGDI1</i> , a mutant <i>TP53</i> -associated Rho GTPase dissociation inhibitor, is overexpressed in gene expression profiles of <i>TP53</i> disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599.	1.2	3
596	European education corridors: opportunity for academic solidarity. <i>Lancet</i> , 2020, 395, 1343.	6.3	3
597	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	2.0	3
598	The Biology of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 266-274.	1.0	3
599	The Pathologic Spectrum of Aids- Related Non-Hodgkin's Lymphomas. , 1999, , 191-202.		3
600	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018, 132, 5565-5565.	0.6	3
601	XPO1 Mutations May Identify Binet I Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment. <i>Blood</i> , 2019, 134, 1743-1743.	0.6	3
602	Phase II Multicentric Exploratory Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009, 114, 860-860.	0.6	3
603	Genetic Mechanisms of Immune Escape in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 1692-1692.	0.6	3
604	BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas. <i>Blood</i> , 1997, 90, 2445-2450.	0.6	3
605	Radiotherapy in COVID-19 patient affected by multiple myeloma: a case report. <i>Translational Cancer Research</i> , 2020, 9, 7662-7668.	0.4	3
606	A step ahead toward precision medicine for chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 2352-2355.	1.7	3
607	Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 777730.	1.3	3
608	Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome. <i>Blood</i> , 2018, 132, 1829-1829.	0.6	3
609	Elastin Microfibril Interferer1 (EMILIN1) is an alternative prosurvival VLA4 ligand in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 181-190.	0.8	3
610	Is plasmablastic lymphoma of the oral cavity an HHV-8-associated disease?. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1251-2.	2.1	3
611	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
612	Morphologic Patterns and Molecular Pathways of Aids-Related Head and Neck and other Systemic Lymphomas. <i>Annals of Otology, Rhinology and Laryngology</i> , 1996, 105, 495-499.	0.6	2

#	ARTICLE	IF	CITATIONS
613	Simian virus 40 infection in lymphoproliferative disorders. <i>Lancet, The</i> , 2003, 361, 1565.	6.3	2
614	Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2010, 196, 89-92.	1.0	2
615	Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. <i>British Journal of Haematology</i> , 2010, 150, 229-232.	1.2	2
616	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , 2014, 99, 1285-1291.	1.7	2
617	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. <i>American Journal of Hematology</i> , 2015, 90, 970-974.	2.0	2
618	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 744.	7.7	2
619	Regulatory agencies should engage in drug pricing. <i>BMJ, The</i> , 2016, 354, i4524.	3.0	2
620	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	0.8	2
621	Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 329-342.	0.5	2
622	Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2525.	1.8	2
623	Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients. <i>Blood</i> , 2018, 132, 1607-1607.	0.6	2
624	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	0.6	2
625	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010, 116, 1371-1371.	0.6	2
626	NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment. <i>Blood</i> , 2012, 120, 1784-1784.	0.6	2
627	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 3047-3047.	0.6	2
628	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	0.6	2
629	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. <i>Blood</i> , 2010, 116, 3375-3375.	0.6	2
630	AIDS-Related Extranodal Non-Hodgkin's Lymphomas With Plasma Cell Differentiation. <i>Blood</i> , 1997, 90, 1337-1337.	0.6	2

#	ARTICLE	IF	CITATIONS
631	Human normal CD5+ B lymphocytes can be induced to differentiate to CD5- B lymphocytes with germinal center cell features. <i>Blood</i> , 1989, 73, 1259-1263.	0.6	2
632	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 48-48.	0.6	2
633	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 115-115.	0.6	2
634	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4440-4440.	0.6	2
635	Druggable Molecular Pathways in Chronic Lymphocytic Leukemia. <i>Life</i> , 2022, 12, 283.	1.1	2
636	Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma. <i>HemaSphere</i> , 2022, 6, e727.	1.2	2
637	PvullRFLP in the cytovillin gene (VIL2) on human chromosome 6q. <i>Nucleic Acids Research</i> , 1992, 20, 1158-1158.	6.5	1
638	<i>IGHD3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 299-302.	1.2	1
639	Tracking the biological risk of coronary artery disease in HIV-infected individuals: the case of circulating endothelial progenitor cells. <i>Aids</i> , 2011, 25, 379-381.	1.0	1
640	rs2072135, a low penetrance variant for chronic lymphocytic leukaemia?. <i>British Journal of Haematology</i> , 2013, 162, 221-228.	1.2	1
641	<i>MYC</i> network mutations in high risk chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2014, 32, 155-157.	0.8	1
642	An anomalous case of acute coronary syndrome. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e118-e121.	0.6	1
643	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. <i>British Journal of Haematology</i> , 2018, 181, 693-695.	1.2	1
644	An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 98-101.	0.2	1
645	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. , 1999, 45, 259.		1
646	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018, 132, 3012-3012.	0.6	1
647	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018, 132, 1834-1834.	0.6	1
648	NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 1832-1832.	0.6	1

#	ARTICLE	IF	CITATIONS
649	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
650	CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. <i>Blood</i> , 2012, 120, 929-929.	0.6	1
651	Differential Distribution Of Recurrent Gene Mutations In Subsets Of Chronic Lymphocytic Leukemia Patients With Stereotyped B-Cell Receptors: Results From A Multicenter Project Of The European Research Initiative On CLL In A Series Of 2482 Cases. <i>Blood</i> , 2013, 122, 4113-4113.	0.6	1
652	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , 2016, 128, 4376-4376.	0.6	1
653	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794.	0.6	1
654	Alteration of BIRC3 and Multiple Other NF- $\kappa$ B Pathway Genes in Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2011, 118, 264-264.	0.6	1
655	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263.	0.6	1
656	Aids-Related Non-Hodgkin Lymphomas. , 1996, , 277-284.		1
657	Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 295-295.	0.6	1
658	Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment. <i>Blood</i> , 2015, 126, 4145-4145.	0.6	1
659	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study. <i>Blood</i> , 2018, 132, 3147-3147.	0.6	1
660	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2838-2838.	0.6	1
661	Reply to Aron P. Kater <i>et al</i> .. <i>Haematologica</i> , 2020, 105, e384-e384.	1.7	1
662	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021, 138, 3746-3746.	0.6	1
663	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	0.6	1
664	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. $\bar{\imath}$ Training/Validation Study. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
665	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. <i>Advances in Hematology</i> , 2022, 2022, 1-10.	0.6	1
666	Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 1100-1104.	0.8	1

#	ARTICLE	IF	CITATIONS
667	Diagnostic and prognostic implications of genetic lesions in non-Hodgkin's lymphoma. <i>European Journal of Cancer</i> , 1996, 32, 1477-1482.	1.3	0
668	CD40 promotes lymphoma from nuclear hideaway. <i>Blood</i> , 2007, 110, 1710-1711.	0.6	0
669	Free light-chains and renal disorders: when small is worse. <i>Lancet, The</i> , 2010, 376, 1221.	6.3	0
670	Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas. <i>Methods in Molecular Biology</i> , 2013, 973, 213-226.	0.4	0
671	Genome-wide <sc>DNA</sc> profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014, 164, 896-899.	1.2	0
672	11. Chronic lymphocytic leukemia. , 2016, , 205-228.		0
673	Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication. <i>Lancet Oncology, The</i> , 2017, 18, 163-164.	5.1	0
674	Cerebrospinal fluid xanthochromia after pegasparginase hepatotoxicity in B-cell acute lymphoblastic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2293-2294.	0.2	0
675	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. <i>HemaSphere</i> , 2021, 5, e639.	1.2	0
676	Immunoglobulin (Ig) Variable Gene Usage Identifies a Subset of Unmutated Chronic Lymphocytic Leukemia (CLL) Patients Expressing 51p1-Like alleles and a Particularly Unfavorable Prognostic Outcome.. <i>Blood</i> , 2004, 104, 1922-1922.	0.6	0
677	Molecular Analysis of Immunoglobulin Variable Genes in HIV-Related Non-Hodgkin Lymphoma: Implications for Disease Pathogenesis and Histogenesis.. <i>Blood</i> , 2005, 106, 330-330.	0.6	0
678	Molecular Analysis of Posttransplant Lymphoproliferative Disorders (PTLD) of Donor Origin Occuring in Liver Transplant Patients.. <i>Blood</i> , 2005, 106, 1916-1916.	0.6	0
679	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007, 110, 3089-3089.	0.6	0
680	Human CD38 Is a Potential Therapeutic Target for Selected Chronic Lymphocytic Leukemia cases.. <i>Blood</i> , 2008, 112, 2096-2096.	0.6	0
681	Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 1260-1260.	0.6	0
682	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. <i>Blood</i> , 2009, 114, 4374-4374.	0.6	0
683	CD38 Induces Homing of Chronic Lymphocytic Leukemia Cells to the Lymphoid Organs through a Functional Interplay with CXCR4.. <i>Blood</i> , 2009, 114, 2328-2328.	0.6	0
684	Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?.. <i>Blood</i> , 2009, 114, 672-672.	0.6	0

#	ARTICLE	IF	CITATIONS
685	Genesis and consequences of genetic lesions in lymphoid neoplasms. , 2010, , 361-379.		0
686	Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study. Blood, 2010, 116, 4953-4953.	0.6	0
687	CD38 Expression Marks CLL Cells with Invasive Properties. Blood, 2010, 116, 2422-2422.	0.6	0
688	CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells. Blood, 2011, 118, 621-621.	0.6	0
689	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2870-2870.	0.6	0
690	Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Preliminary Results of the Unit Study.. Blood, 2012, 120, 2192-2192.	0.6	0
691	The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. Blood, 2012, 120, 1772-1772.	0.6	0
692	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 3653-3653.	0.6	0
693	Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. Blood, 2013, 122, 1614-1614.	0.6	0
694	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. Blood, 2015, 126, 2099-2099.	0.6	0
695	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. Blood, 2015, 126, 2925-2925.	0.6	0
696	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	0.6	0
697	Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).. Journal of Clinical Oncology, 2016, 34, 7545-7545.	0.8	0
698	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4367-4367.	0.6	0
699	Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.. Journal of Clinical Oncology, 2017, 35, 7538-7538.	0.8	0
700	The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. Blood, 2018, 132, 2890-2890.	0.6	0
701	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood, 2018, 132, 2861-2861.	0.6	0
702	Early progression of disease (POD24) as survival predictor in MALT lymphoma.. Journal of Clinical Oncology, 2019, 37, 7548-7548.	0.8	0



#	ARTICLE	IF	CITATIONS
703	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
704	POEMS and calciphylaxis: a novel association?. <i>Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societ� Italiana Di Medicina Interna</i> , 2004, 19, 235-7.	0.1	0
705	Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, , .	1.2	0
706	Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. <i>Hematological Oncology</i> , 2022, 40, 1105-1108.	0.8	0